Oral MS drug Cladribine 'Shuts Down MS Activity'
Posted: Wed Jun 09, 2010 2:53 am

Cladribine, an oral drug already marketed for hematologic cancers under the trade name Leustatin, was superior to placebo in reducing progression and other signs of MS disease activity, researchers reported at CMSC-ACTRIMS.
Freedom from any disease activity, including relapse, disability progression, or MRI progression, was experienced by 44.3% of patients treated with a high-dose of cladribine, and 43% of patients randomized to a low-dose regimen compared with 16% of placebo patients (P<0.001), said Gavin Giovannoni, PhD, from the Blizard Institute of Cell and Molecular Science at the Barts and the London School of Medicine and Dentistry in London, England.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629